Biotricity

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It is also involved in delivering remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology is comprised of monitoring device and software components, which are made available to the market to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. It operates through the following segments: Resting (Non-stress) ECG Systems, Stress ECG Systems, and Holter Monitoring Systems. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Company Delivers Revenue Growth in 9 Out of the last 10 Consecutive Quarters REDWOOD CITY, CA / ACCESSWIRE / November 21, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it has surpassed $10 million in annual revenue run rate. "With strong revenue growth each quarter, our scale and market reach increases every day," says Biotricity Founder and CEO, Dr. Waqaas Al-Siddiq.

Biotricity Surpasses $10 Million in Annual Revenue Run Rate

Recent announcement with Top 10 National Medical Distributor underscores Company's expanded footprint REDWOOD CITY, CA / ACCESSWIRE / November 18, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, provided a recap of its recent operational and corporate activities and discussed the Company's distribution strategy for the second half of FY 2023 ending March 31, 2023. Recent Operating and Corporate Highlights Recently signed a distribution agreement with a Top 10 US medical distributor for sales of its flagship cardiac monitoring solutions, Bioflux and Biotres.

Biotricity Provides Updates on its Operational and Expansion Strategy

REDWOOD CITY, CA / ACCESSWIRE / November 16, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has signed a distribution agreement with one of the Top 10 US medical device distributors . to distribute its cardiac monitoring solutions, Bioflux and Biotres.

Biotricity Signs Distribution Agreement to Expand Access for its Cardiac Monitoring Solutions

Biotricity, Inc. (NASDAQ:BTCY ) Q2 2023 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Waqaas Al-Siddiq - Chairman, Chief Executive Officer & Founder John Ayanoglou - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Michael Donovan - H.C. Wainwright Operator Good day, and welcome to the Biotricity's Fiscal Second Quarter 2023 Financial Results Conference Call.

Biotricity, Inc. (BTCY) Q2 2023 Earnings Call Transcript

Revenue totaled $2.4 million, up 14% sequentially quarter-over-quarter REDWOOD CITY, CA / ACCESSWIRE / November 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022. "We are pleased with our steady revenue growth year-over-year and sequentially for the fiscal second quarter.

Biotricity Reports Financial Results for Fiscal 2023 Second Quarter

Bioheart provides consumers the most advanced personal heart monitoring technology, combining powerful analytics and continuous heart monitoring for personalized heart insights REDWOOD CITY, CA / ACCESSWIRE / November 10, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that its Bioheart device has been named to TIME's list of the Best Inventions of 2022. Bioheart is the first of its kind - a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights.

Biotricity's Bioheart Named to TIME's List of The Best Inventions of 2022

REDWOOD CITY, CA / ACCESSWIRE / November 1, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference call on Monday, November 14, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter and provide a business update.

Biotricity to Host Fiscal 2023 Second Quarter Financial Results on November 14th at 4:30 PM ET

Biocare Cardiac is the first-of-its-kind comprehensive cardiac disease management solution combining diagnostics, RPM, disease and lifestyle management, and telemedicine for cardiologists and patients. REDWOOD CITY, CA / ACCESSWIRE / October 26, 2022 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the U.S. launch of Biocare Cardiac.

Biotricity Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics

REDWOOD CITY, CA / ACCESSWIRE / October 13, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that Waqaas Al-Siddiq, Founder and CEO, is scheduled to participate in a panel discussion at the American Medical Device Summit on October 19, 2022 in Chicago, Illinois. American Medical Device Summit: Location: Westin Chicago Lombard, Chicago, IllinoisFormat: Panel Discussion "The Evolving Role of Medical Devices in Delivering At-Home Patient Care"Date: Wednesday, October 19th at 4:20 p.m.

Biotricity CEO, Waqaas Al-Siddiq, to Participate in Panel Discussion on the Evolution of Medical Devices at the American Medical Device Summit on October 19th

Data set of 2 billion heartbeats and growing allows Biotricity to scale faster and operate more efficiently with better automation, yielding growth and better margins in the future REDWOOD CITY, CA / ACCESSWIRE / October 4, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity's high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient's ECG information, has captured billions of heartbeats to date, monitored in real-time by Bioflux's built in algorithms, certified cardiac technicians and benchmarked by Artificial Intelligence (AI).

Biotricity Surpasses 2 billion Recorded and Analyzed Heartbeats for Atrial Fibrillation (AFib)

Bioflux-AI is an innovative artificial intelligence-driven (‘AI') system with real-time monitoring and prediction capabilities that will be used to investigate stroke episodes in Chronic Kidney Disease patients REDWOOD CITY, CA / ACCESSWIRE / September 7, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity's innovative artificial intelligence-driven (‘AI') system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease (‘CKD'). The risk of ischemic and hemorrhagic stroke is 5 to 30 times higher in patients with CKD and has a mortality rate of up to three times that of the general population.

Biotricity Wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled Real-Time Monitoring and Predictive Analytics for Stroke due to Chronic Kidney Failure

Biotricity, Inc. (NASDAQ:BTCY ) Q1 2023 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Waqaas Siddiq - Chairman, Chief Executive Officer and Founder John Ayanoglou - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital markets Kevin Dede - HC Wainwright Operator Good day and welcome to the Biotricity's Fiscal First Quarter 2023 Financial Results Conference Call. Today's conference is being recorded.

Biotricity, Inc. (BTCY) CEO Waqaas Siddiq on Q1 2023 Results - Earnings Call Transcript

REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network.

Biotricity Reports Financial Results for Fiscal 2023 First Quarter

REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 /bbBiotricity Inc. (NYSE:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference call and webcast on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter 2023 and provide a business update.

Biotricity to Host Fiscal First Quarter 2023 Financial Results Conference Call on August 15th at 4:30 p.m. ET

Today, we take our first look at a small medical device maker called Biotricity. Impressive growth projections lie ahead for this Busted IPO as it recently launched several important new products.

Biotricity, Inc.: A First Take

Company Reports Record Revenue and Improved Margins REDWOOD CITY, CA / ACCESSWIRE / July 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2022 fourth quarter and year ended March 31, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "Fiscal 2022 was a pivotal year for Biotricity as we made significant strides in our product development and commercialization strategy.

Biotricity Reports Financial Results for Fiscal 2022 Fourth Quarter and Full Year

REDWOOD CITY, CA / ACCESSWIRE / June 23, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that the Company is expected to join the Russell Microcap® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022. Membership in the Russell Microcap® Index, which remains in place for one year, includes inclusion in the appropriate growth and value style indexes.

Biotricity to Join Russell Microcap(R) Index

REDWOOD CITY, CA / ACCESSWIRE / May 23, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is scheduled to present and will be participating in a fireside chat at the H.C. Wainwright Global Investment Conference, being held from May 23-26, 2022.

Biotricity to Present at the 2022 H.C. Wainwright Global Investment Conference on Tuesday May 24th

Company highlights recent achievements and strategic initiatives setting the foundation to drive revenue growth to record levels in calendar 2022 National sales force growing, now covers 27 states for in-office clinic and physician demos With Covid fading, Company expects new opportunities for its sales team REDWOOD CITY, CA / ACCESSWIRE / May 5, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today provided an update for its shareholders by Chief Executive Officer Waqaas Al-Siddiq, Ph.D., that discusses recent Company achievements and strategic initiatives to position the business for strong 2022 results, increasing scale and accelerating growth into 2023.

Biotricity Issues Shareholder Update

Company reports pre-order sales from existing customers of its wireless wearable device for early detection of cardiac arrhythmias REDWOOD CITY, CA / ACCESSWIRE / March 22, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.

Biotricity to Launch Commercial Sales of Its Disruptive Cardiac Monitoring Device, Biotres in April 2022

Leader in early-detection cardiac diagnostics monitoring solutions joins the ranks of Canva, Microsoft, SpaceX, and more REDWOOD CITY, CA / ACCESSWIRE / March 8, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2022. Biotricity was also highlighted as #1 in this year's Medical Devices category.

Biotricity Named to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022

Follows fiscal third quarter earnings that saw revenue up 93% year-over-year and Company's highest-ever quarterly cash position Biotricity now taking preorders for Biotres, an FDA-cleared, wireless, wearable cardiac arrhythmia monitoring device REDWOOD CITY, CA / ACCESSWIRE / March 4, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it will attend the 34th Annual Roth Conference, being held on March 13-15, 2022 at The Ritz Carlton, Laguna Niguel in Dana Point, California. The conference is one of the largest in the nation for small-cap companies.

Biotricity, Inc. to Attend 34th Annual Roth Conference March 13th-15th

Announcement follows FDA clearance Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022 REDWOOD CITY, CA / ACCESSWIRE / February 23, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company's three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. The Company believes that its wireless, wearable Biotres device offers a secondary product for doctors and hospitals to meet their patients' cardiac monitoring needs and addresses the $5.7 billion cardiac arrhythmia monitoring devices market.

Biotricity Now Taking Pre-Orders for its Biotres Wireless Wearable Cardiac Monitoring Device

Biotricity's (BTCY) CEO Waqaas Al-Siddiq on Q3 2022 Results - Earnings Call Transcript

Management to host investor call on Tuesday February 15th at 4:15 pm ET 93% YOY Revenue Gains to $1.93 Million Revenue Outpaces SG&A Increase by 2.2x Cash Position of $16.8 Million at Quarter End Is Highest Ever Continues to Anticipate Full-Year Triple-Digit Revenue Growth REDWOOD CITY, CA / ACCESSWIRE / February 14, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year's third quarter ended December 31, 2021. Q3-FY22 financial and operating highlights include: Revenue of $1.93 million, an increase of 93% year-over-year and sequentially 7% above the $1.8- million reported in Q2FY22.

News for Biotricity Stock (BTCY)